Literature DB >> 31194639

Concurrent Treatment for PTSD and Prolonged Grief Disorder: Review of Outcomes for Exposure- and Nonexposure-Based Treatments.

Jasmine R Eddinger1, Madeleine M Hardt1, Joah L Williams1.   

Abstract

This review gives an overview of treatments used to concurrently reduce symptoms of posttraumatic stress disorder (PTSD) and prolonged grief disorder (PGD). For purposes of this review, emphasis is placed on locating and comparing literature on exposure- and nonexposure-based treatments. Across 14 studies, the overall findings suggest that treatments are generally effective in treating PTSD and PGD concurrently and that treatments incorporating exposure-based components performed similarly to those without exposure-based components. However, methodological limitations preclude the ability to draw firm conclusions about the added impact of exposure-based components in traumatic grief treatment. Future directions for research on concurrent treatments for PTSD and PGD are discussed.

Entities:  

Keywords:  PTSD; exposure; prolonged grief; treatment; violent loss

Year:  2019        PMID: 31194639     DOI: 10.1177/0030222819854907

Source DB:  PubMed          Journal:  Omega (Westport)        ISSN: 0030-2228


  3 in total

1.  Loss-Related Characteristics and Symptoms of Depression, Prolonged Grief, and Posttraumatic Stress Following Suicide Bereavement.

Authors:  Raphaela Grafiadeli; Heide Glaesmer; Birgit Wagner
Journal:  Int J Environ Res Public Health       Date:  2022-08-18       Impact factor: 4.614

2.  Managing Grief of Bereaved Families During the COVID-19 Pandemic in Japan.

Authors:  Yoko Matsuda; Yoshitake Takebayashi; Satomi Nakajima; Masaya Ito
Journal:  Front Psychiatry       Date:  2021-06-04       Impact factor: 4.157

3.  Post-Migration Stressors and Their Association With Symptom Reduction and Non-Completion During Treatment for Traumatic Grief in Refugees.

Authors:  A A A Manik J Djelantik; Annemiek de Heus; Diede Kuiper; Rolf J Kleber; Paul A Boelen; Geert E Smid
Journal:  Front Psychiatry       Date:  2020-05-27       Impact factor: 4.157

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.